Joel Beatty
Stock Analyst at Baird
(4.33)
# 359
Out of 4,944 analysts
196
Total ratings
42.77%
Success rate
21.76%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $11.56 | -22.11% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $116.75 | +24.20% | 7 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $25.45 | +21.81% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $19.17 | +25.20% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.29 | +74.67% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $19.94 | +150.75% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $637.40 | +6.68% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $13.22 | +119.36% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $45.27 | +45.79% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $113.33 | +36.77% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $105.23 | +53.95% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $27.43 | +49.47% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.70 | +170.27% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $10.15 | +57.64% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $6.75 | +137.04% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $48.46 | +50.64% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $20.34 | +57.33% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $39.49 | +89.92% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $8.20 | +34.15% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.70 | +311.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $56.86 | +14.32% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $28.11 | +156.14% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $5.29 | +4,436.86% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.35 | +233.33% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $10.02 | +149.50% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.32 | +2,682.93% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $12.97 | +115.88% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.42 | +561.16% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.01 | -37.81% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.68 | +2,519.05% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $17.80 | +225.84% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $23.62 | +1.63% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $14.89 | +20.89% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.43 | +146.91% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.30 | +2,284.62% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $4.36 | +542.94% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $429.93 | -59.30% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.31 | +224.83% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.80 | +474.47% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $41.41 | +88.36% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.81 | +919.37% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $14.88 | +706.45% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $2.58 | +17,341.86% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.79 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.48 | +76.89% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.62 | +19,412.20% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $6.20 | +206.45% | 3 | Nov 10, 2017 |
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $11.56
Upside: -22.11%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $116.75
Upside: +24.20%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $25.45
Upside: +21.81%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.17
Upside: +25.20%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.29
Upside: +74.67%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $19.94
Upside: +150.75%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $637.40
Upside: +6.68%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $13.22
Upside: +119.36%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $45.27
Upside: +45.79%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $113.33
Upside: +36.77%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $105.23
Upside: +53.95%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $27.43
Upside: +49.47%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.70
Upside: +170.27%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $10.15
Upside: +57.64%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $6.75
Upside: +137.04%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $48.46
Upside: +50.64%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $20.34
Upside: +57.33%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $39.49
Upside: +89.92%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $8.20
Upside: +34.15%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.70
Upside: +311.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $56.86
Upside: +14.32%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $28.11
Upside: +156.14%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $5.29
Upside: +4,436.86%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.35
Upside: +233.33%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $10.02
Upside: +149.50%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.32
Upside: +2,682.93%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $12.97
Upside: +115.88%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.42
Upside: +561.16%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.01
Upside: -37.81%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.68
Upside: +2,519.05%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $17.80
Upside: +225.84%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $23.62
Upside: +1.63%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $14.89
Upside: +20.89%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.43
Upside: +146.91%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.30
Upside: +2,284.62%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $4.36
Upside: +542.94%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $429.93
Upside: -59.30%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.31
Upside: +224.83%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.80
Upside: +474.47%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $41.41
Upside: +88.36%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $9.81
Upside: +919.37%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $14.88
Upside: +706.45%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $2.58
Upside: +17,341.86%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.79
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.48
Upside: +76.89%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.62
Upside: +19,412.20%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $6.20
Upside: +206.45%